Hughes, Steven G.

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 754

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 669

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 573

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 528

Targeting APOC3 in the familial chylomicronemia syndrome

Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 491

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

Tsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 460

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine

RNA Interference and Gene DeliveryCytokine Signaling Pathways and Interactions

Cited by 445

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

Alexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019) · European Heart Journal

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 231

Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes

Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 170

The Effects of 2′- O -Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials

Crooke, S. T., Baker, B. F., Witztum, J. L., Kwoh, T. J., Pham, N. C., Salgado, N., McEvoy, B. W., Cheng, W., Hughes, S. G., Bhanot, S., et al. (2017) · Nucleic Acid Therapeutics

RNA Interference and Gene DeliveryPlatelet Disorders and Treatments

Cited by 129

A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine

Low, J. G., de Alwis, R., Chen, S., Kalimuddin, S., Leong, Y. S., Mah, T. K. L., Yuen, N., Tan, H. C., Zhang, S. L., Sim, J. X. Y., et al. (2022) · npj Vaccines

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 61

Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of Lipidologist

Gaudet, D., Blom, D., Bruckert, E., Stroes, E., Kastelein, J., John, K., Malloy, M., Moulin, P., Retterstøļl, K., Hughes, S., et al. (2016) · Journal of Clinical Lipidology

Pancreatitis Pathology and TreatmentLipid metabolism and disorders

Cited by 30

A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults

Low, J. G., de Alwis, R., Chen, S., Kalimuddin, S., Leong, Y. S., Mah, T. K. L., Yuen, N., Tan, H. C., Zhang, S. L., Sim, J. X. Y., et al. (2021) · medRxiv

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 19